Sandbox Reserved 430: Difference between revisions

From Proteopedia
Jump to navigationJump to search
Student (talk | contribs)
No edit summary
Student (talk | contribs)
mNo edit summary
Line 38: Line 38:


==Additional Features==
==Additional Features==
Acute coronary syndrome, a condition in which there is sudden blockage of blood flow to the heart, is majorly caused by a disease known as atherothrombosis. P2Y12 receptors are a source of anti platelet therapy for the prevention of these conditions. Clopidogrel in complex with P2Y12 in combination with aspirin has guaranteed benefits, however many of the patients treated with clopidogrel-linked P2Y12 with insufficient P2Y12-inhibition experienced inimical side effects. Drug-drug interactions, obesity, diabetes mellitus (DM), reduced left ventricular function and inflammation are all associated with inadequate response to clopidogrel therapy. Clopidogrel is a pro-drug and thienopyridine-type inhibitor of the P2Y12 receptor, which requires Cytochrome P450 to hepatic ally transform it to exert its anti platelet effect. <scene name='48/483887/P450/1'>Click Here</scene> to see this interaction between the P450 complex and Clopidogrel.
Acute coronary syndrome, a condition in which there is sudden blockage of blood flow to the heart, is majorly caused by a disease known as atherothrombosis. This disease is characterized by blocked arteries due to thrombosis: formation of a clot within a blood vessel. The P2Y12 protein is an important platelet receptor inhibitor that can be combined with aspirin in the management of ACS. It regulates certain functions through purinergic signaling, which is a form of extracellular signaling mediated by purine nucleotides and nucleosides like ADP and ATP.
 
The P2Y12 receptor is mainly found on the surface of blood platelets, and functions as a regulator in platelet activation and therefore blood clotting. The P2Y12 receptor is a G-protein coupled receptor, a seven-transmembrane domain protein linked to the cAMP-signaling pathway.  It mediates platelet activation by decreasing intracellular cAMP levels through inhibition of an AC-mediated signaling pathway. Acting as a chemoreceptor, P2Y12 utilizes ADP as an agonist, which initiates ADP-induced platelet aggregation. Clopidogrel in covalent binding complex with P2Y12 acts as an antiplatelet agent, specifically as an ADP receptor inhibitor to decrease platelet aggregation and inhibit thrombus formation.
Clopidogrel is a pro-drug and thienopyridine-type inhibitor of the P2Y12 receptor, which requires Cytochrome P450 to hepatically transform it to exert its anti platelet effect. <scene name='48/483887/P450/1'>Click Here</scene> to see this interaction between the P450 complex and Clopidogrel.
 


==Quiz Question 1==
==Quiz Question 1==